STAT

DECEMBER 10, 2022

Whenever a hematopoietic cell transplant patient tries to get a family member to sneak food in past the nurses, Federico Stella, a resident hematologist at the University of Milan, remembers. One was a girl who tried to get her sister to bring her a panettone, a Milanese sweet bread usually eaten around the holidays. A week before Christmas, the sister tried to hide the panettone in a bag.

145

145

Pharma Tutor

DECEMBER 10, 2022

Pharmacists migration to Australia and New Zealand gets easier now with Academically.ai. admin. Sat, 12/10/2022 - 15:42. Academically.ai, We are an Australian healthcare education technology (EdTech) start-up based in Sydney. We provide courses that will prepare pharmacists to practice, getting a job and migrate to Australia and New Zealand. To put it simply, we intend to enter the Indian market because the majority of pharmacists are underpaid, and many are unaware of such vast potential outsid

108

108

STAT

DECEMBER 10, 2022

NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about one-third of patients with advanced leukemia, according to updates Saturday from separate clinical trials. Two biotechs — Syndax Pharmaceuticals and Kura Oncology — are developing their own versions of so-called menin inhibitors that have the potential to become effective treatments for certain types of genetically defined acute myeloid leukemia (AML), a rapidly progressing bone mar

133

133

Pharmacy Times

DECEMBER 10, 2022

Low socioeconomic status was associated with greater in-hospital mortality and decreased use of advanced therapeutic options.

Hospitals 123

Hospitals 123

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

DECEMBER 10, 2022

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation. The data, presented Saturday at the annual American Society of Hematology conferences, wowed a crowd of attendees, including clinicians who began excitedly imagining how to use the new drug in practice.

Immunization 117

Immunization 117

Fierce Pharma

DECEMBER 10, 2022

ASH: With immune thrombocytopenia win, argenx proves efgartigimod’s no one-trick pony in autoimmune disease. fkansteiner. Sat, 12/10/2022 - 09:12.

Immunization 98

Immunization 98

Pharmacy Times

DECEMBER 10, 2022

Expert discusses analysis of phase 3 MEDALIST trial data aimed to assess the probability of greater overall survival and progression-free survival benefit from luspatercept vs placebo.

65

65

Fierce Pharma

DECEMBER 10, 2022

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle. aliu. Sat, 12/10/2022 - 22:30.

84

84

Pharmacy Times

DECEMBER 10, 2022

In recent decades, clinical trials have grown increasingly restrictive and exclusive, which has impacted the inclusivity and diversity of selected trial participants.

65

65

STAT

DECEMBER 10, 2022

NEW ORLEANS — Adicet Bio generated a good deal of buzz last June with a unique, off-the-shelf therapy made from a special type of T cell that induced complete remissions in patients with advanced and aggressive B cell lymphomas. But an update reported Saturday showed patients starting to relapse, which may raise questions about the so-called gamma-delta T cell therapy’s durability.

98

98

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

DECEMBER 10, 2022

Following a phase 2 analysis of OP-1250 with palbociclib, researchers recommend an OP-1250 dose level of 120 mg/day for future trials.

73

73

Board Vitals - Pharmacist

DECEMBER 10, 2022

When it comes to medical information, there may not be a more entertaining way to receive it than through a TikTok video. There are many people creating these informative videos, but did you know there are lots of doctors on TikTok that you can follow? And with more than 1.5 billion monthly users (as of Q4 in 2022), TikTok is easily one of the most popular social media sites.

Medical Schools 52

Medical Schools 52

Pharmacy Times

DECEMBER 10, 2022

Guidelines for HER2-low expressed cancer could define who and how patient recieve drugs, said expert live from San Antonio Breast Cancer Symposium 2022.

65

65